Recommendations for the implementation of BRCA testing in ovarian cancer patients and their relatives
[Display omitted] The current availability of new Poly(ADP-ribose) Polymerase (PARP)-inhibitors for the treatment of ovarian cancer patients independently of the presence of a BRCA pathogenic variant, together with the validation of somatic test for the analysis of BRCA1/2 genes, involves the need t...
Gespeichert in:
| Veröffentlicht in: | Critical reviews in oncology/hematology 2019-08, Vol.140, p.67-72 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 72 |
|---|---|
| container_issue | |
| container_start_page | 67 |
| container_title | Critical reviews in oncology/hematology |
| container_volume | 140 |
| creator | Gori, Stefania Barberis, Massimo Bella, Maria Angela Buttitta, Fiamma Capoluongo, Ettore Carrera, Paola Colombo, Nicoletta Cortesi, Laura Genuardi, Maurizio Gion, Massimo Guarneri, Valentina Incorvaia, Lorena La Verde, Nicla Lorusso, Domenica Marchetti, Antonio Marchetti, Paolo Normanno, Nicola Pasini, Barbara Pensabene, Matilde Pignata, Sandro Radice, Paolo Ricevuto, Enrico Sapino, Anna Tagliaferri, Pierosandro Tassone, Pierfrancesco Trevisiol, Chiara Truini, Mauro Varesco, Liliana Russo, Antonio |
| description | [Display omitted]
The current availability of new Poly(ADP-ribose) Polymerase (PARP)-inhibitors for the treatment of ovarian cancer patients independently of the presence of a BRCA pathogenic variant, together with the validation of somatic test for the analysis of BRCA1/2 genes, involves the need to optimise the guidelines for BRCA testing.
The AIOM-SIGU-SIBIOC-SIAPEC-IAP Italian Scientific Societies, in this position paper, recommend the implementation of BRCA testing with 2 main objectives: the first is the identification of ovarian cancer patients with higher probability of benefit from specific anticancer treatments (test for response to therapy); the second goal, through BRCA testing in the family members of ovarian cancer patients, is the identification of carriers of pathogenic variant, who have inheredited predisposition to cancer development (test for cancer risk). These individuals with increased risk of cancer, should be encouraged to participate in dedicated high-risk surveillance clinics and specific risk-reducing measures (primary and/or secondary prevention programs). |
| doi_str_mv | 10.1016/j.critrevonc.2019.05.012 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2242159178</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1040842819301040</els_id><sourcerecordid>2242159178</sourcerecordid><originalsourceid>FETCH-LOGICAL-c424t-1f7357d04ac58a6cffdb4fca9f6b0c18cc28d21374bdd9d35d7daa73c4df2c353</originalsourceid><addsrcrecordid>eNqFkE1LxDAQhoMofv8FydFLa5KmTXvUxS8QBNFzyE4mmqVt1qS74L836_px9DTDyzMzyUMI5azkjDcXixKinyKuwwilYLwrWV0yLnbIIW9VVzDZ8N3cM8mKVor2gByltGCMSdmofXJQca4aoapDgk8IYRhwtGbyYUzUhUinN6R-WPaY8-krp8HRq6fZJZ0wTX58pT5HaxO9GSmYETDSZQYznqgZ7WaDjzRin8M1phOy50yf8PS7HpOXm-vn2V3x8Hh7P7t8KEAKORXcqapWlkkDdWsacM7OpQPTuWbOgLcAorWCV0rOre1sVVtljVEVSOsEVHV1TM63e5cxvK_yU_XgE2DfmxHDKmkhpOB1x1Wb0XaLQgwpRXR6Gf1g4ofmTG8k64X-k6w3kjWrdZacR8--r6zmA9rfwR-rGbjaApj_uvYYdYLsBtD6iDBpG_z_Vz4BAgmVtw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2242159178</pqid></control><display><type>article</type><title>Recommendations for the implementation of BRCA testing in ovarian cancer patients and their relatives</title><source>Access via ScienceDirect (Elsevier)</source><creator>Gori, Stefania ; Barberis, Massimo ; Bella, Maria Angela ; Buttitta, Fiamma ; Capoluongo, Ettore ; Carrera, Paola ; Colombo, Nicoletta ; Cortesi, Laura ; Genuardi, Maurizio ; Gion, Massimo ; Guarneri, Valentina ; Incorvaia, Lorena ; La Verde, Nicla ; Lorusso, Domenica ; Marchetti, Antonio ; Marchetti, Paolo ; Normanno, Nicola ; Pasini, Barbara ; Pensabene, Matilde ; Pignata, Sandro ; Radice, Paolo ; Ricevuto, Enrico ; Sapino, Anna ; Tagliaferri, Pierosandro ; Tassone, Pierfrancesco ; Trevisiol, Chiara ; Truini, Mauro ; Varesco, Liliana ; Russo, Antonio</creator><creatorcontrib>Gori, Stefania ; Barberis, Massimo ; Bella, Maria Angela ; Buttitta, Fiamma ; Capoluongo, Ettore ; Carrera, Paola ; Colombo, Nicoletta ; Cortesi, Laura ; Genuardi, Maurizio ; Gion, Massimo ; Guarneri, Valentina ; Incorvaia, Lorena ; La Verde, Nicla ; Lorusso, Domenica ; Marchetti, Antonio ; Marchetti, Paolo ; Normanno, Nicola ; Pasini, Barbara ; Pensabene, Matilde ; Pignata, Sandro ; Radice, Paolo ; Ricevuto, Enrico ; Sapino, Anna ; Tagliaferri, Pierosandro ; Tassone, Pierfrancesco ; Trevisiol, Chiara ; Truini, Mauro ; Varesco, Liliana ; Russo, Antonio ; On behalf of the AIOM-SIGU-SIBIOC-SIAPEC-IAP Working Group ; AIOM-SIGU-SIBIOC-SIAPEC-IAP Working Group</creatorcontrib><description>[Display omitted]
The current availability of new Poly(ADP-ribose) Polymerase (PARP)-inhibitors for the treatment of ovarian cancer patients independently of the presence of a BRCA pathogenic variant, together with the validation of somatic test for the analysis of BRCA1/2 genes, involves the need to optimise the guidelines for BRCA testing.
The AIOM-SIGU-SIBIOC-SIAPEC-IAP Italian Scientific Societies, in this position paper, recommend the implementation of BRCA testing with 2 main objectives: the first is the identification of ovarian cancer patients with higher probability of benefit from specific anticancer treatments (test for response to therapy); the second goal, through BRCA testing in the family members of ovarian cancer patients, is the identification of carriers of pathogenic variant, who have inheredited predisposition to cancer development (test for cancer risk). These individuals with increased risk of cancer, should be encouraged to participate in dedicated high-risk surveillance clinics and specific risk-reducing measures (primary and/or secondary prevention programs).</description><identifier>ISSN: 1040-8428</identifier><identifier>EISSN: 1879-0461</identifier><identifier>DOI: 10.1016/j.critrevonc.2019.05.012</identifier><identifier>PMID: 31176273</identifier><language>eng</language><publisher>Netherlands: Elsevier B.V</publisher><subject>BRCA1 ; BRCA2 ; Genetic testing ; Germline mutations ; Ovarian cancer ; PARP inhibitors ; Somatic mutations</subject><ispartof>Critical reviews in oncology/hematology, 2019-08, Vol.140, p.67-72</ispartof><rights>2019 The Authors</rights><rights>Copyright © 2019 The Authors. Published by Elsevier B.V. All rights reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c424t-1f7357d04ac58a6cffdb4fca9f6b0c18cc28d21374bdd9d35d7daa73c4df2c353</citedby><cites>FETCH-LOGICAL-c424t-1f7357d04ac58a6cffdb4fca9f6b0c18cc28d21374bdd9d35d7daa73c4df2c353</cites><orcidid>0000-0002-4370-2008</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.critrevonc.2019.05.012$$EHTML$$P50$$Gelsevier$$Hfree_for_read</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31176273$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Gori, Stefania</creatorcontrib><creatorcontrib>Barberis, Massimo</creatorcontrib><creatorcontrib>Bella, Maria Angela</creatorcontrib><creatorcontrib>Buttitta, Fiamma</creatorcontrib><creatorcontrib>Capoluongo, Ettore</creatorcontrib><creatorcontrib>Carrera, Paola</creatorcontrib><creatorcontrib>Colombo, Nicoletta</creatorcontrib><creatorcontrib>Cortesi, Laura</creatorcontrib><creatorcontrib>Genuardi, Maurizio</creatorcontrib><creatorcontrib>Gion, Massimo</creatorcontrib><creatorcontrib>Guarneri, Valentina</creatorcontrib><creatorcontrib>Incorvaia, Lorena</creatorcontrib><creatorcontrib>La Verde, Nicla</creatorcontrib><creatorcontrib>Lorusso, Domenica</creatorcontrib><creatorcontrib>Marchetti, Antonio</creatorcontrib><creatorcontrib>Marchetti, Paolo</creatorcontrib><creatorcontrib>Normanno, Nicola</creatorcontrib><creatorcontrib>Pasini, Barbara</creatorcontrib><creatorcontrib>Pensabene, Matilde</creatorcontrib><creatorcontrib>Pignata, Sandro</creatorcontrib><creatorcontrib>Radice, Paolo</creatorcontrib><creatorcontrib>Ricevuto, Enrico</creatorcontrib><creatorcontrib>Sapino, Anna</creatorcontrib><creatorcontrib>Tagliaferri, Pierosandro</creatorcontrib><creatorcontrib>Tassone, Pierfrancesco</creatorcontrib><creatorcontrib>Trevisiol, Chiara</creatorcontrib><creatorcontrib>Truini, Mauro</creatorcontrib><creatorcontrib>Varesco, Liliana</creatorcontrib><creatorcontrib>Russo, Antonio</creatorcontrib><creatorcontrib>On behalf of the AIOM-SIGU-SIBIOC-SIAPEC-IAP Working Group</creatorcontrib><creatorcontrib>AIOM-SIGU-SIBIOC-SIAPEC-IAP Working Group</creatorcontrib><title>Recommendations for the implementation of BRCA testing in ovarian cancer patients and their relatives</title><title>Critical reviews in oncology/hematology</title><addtitle>Crit Rev Oncol Hematol</addtitle><description>[Display omitted]
The current availability of new Poly(ADP-ribose) Polymerase (PARP)-inhibitors for the treatment of ovarian cancer patients independently of the presence of a BRCA pathogenic variant, together with the validation of somatic test for the analysis of BRCA1/2 genes, involves the need to optimise the guidelines for BRCA testing.
The AIOM-SIGU-SIBIOC-SIAPEC-IAP Italian Scientific Societies, in this position paper, recommend the implementation of BRCA testing with 2 main objectives: the first is the identification of ovarian cancer patients with higher probability of benefit from specific anticancer treatments (test for response to therapy); the second goal, through BRCA testing in the family members of ovarian cancer patients, is the identification of carriers of pathogenic variant, who have inheredited predisposition to cancer development (test for cancer risk). These individuals with increased risk of cancer, should be encouraged to participate in dedicated high-risk surveillance clinics and specific risk-reducing measures (primary and/or secondary prevention programs).</description><subject>BRCA1</subject><subject>BRCA2</subject><subject>Genetic testing</subject><subject>Germline mutations</subject><subject>Ovarian cancer</subject><subject>PARP inhibitors</subject><subject>Somatic mutations</subject><issn>1040-8428</issn><issn>1879-0461</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><recordid>eNqFkE1LxDAQhoMofv8FydFLa5KmTXvUxS8QBNFzyE4mmqVt1qS74L836_px9DTDyzMzyUMI5azkjDcXixKinyKuwwilYLwrWV0yLnbIIW9VVzDZ8N3cM8mKVor2gByltGCMSdmofXJQca4aoapDgk8IYRhwtGbyYUzUhUinN6R-WPaY8-krp8HRq6fZJZ0wTX58pT5HaxO9GSmYETDSZQYznqgZ7WaDjzRin8M1phOy50yf8PS7HpOXm-vn2V3x8Hh7P7t8KEAKORXcqapWlkkDdWsacM7OpQPTuWbOgLcAorWCV0rOre1sVVtljVEVSOsEVHV1TM63e5cxvK_yU_XgE2DfmxHDKmkhpOB1x1Wb0XaLQgwpRXR6Gf1g4ofmTG8k64X-k6w3kjWrdZacR8--r6zmA9rfwR-rGbjaApj_uvYYdYLsBtD6iDBpG_z_Vz4BAgmVtw</recordid><startdate>20190801</startdate><enddate>20190801</enddate><creator>Gori, Stefania</creator><creator>Barberis, Massimo</creator><creator>Bella, Maria Angela</creator><creator>Buttitta, Fiamma</creator><creator>Capoluongo, Ettore</creator><creator>Carrera, Paola</creator><creator>Colombo, Nicoletta</creator><creator>Cortesi, Laura</creator><creator>Genuardi, Maurizio</creator><creator>Gion, Massimo</creator><creator>Guarneri, Valentina</creator><creator>Incorvaia, Lorena</creator><creator>La Verde, Nicla</creator><creator>Lorusso, Domenica</creator><creator>Marchetti, Antonio</creator><creator>Marchetti, Paolo</creator><creator>Normanno, Nicola</creator><creator>Pasini, Barbara</creator><creator>Pensabene, Matilde</creator><creator>Pignata, Sandro</creator><creator>Radice, Paolo</creator><creator>Ricevuto, Enrico</creator><creator>Sapino, Anna</creator><creator>Tagliaferri, Pierosandro</creator><creator>Tassone, Pierfrancesco</creator><creator>Trevisiol, Chiara</creator><creator>Truini, Mauro</creator><creator>Varesco, Liliana</creator><creator>Russo, Antonio</creator><general>Elsevier B.V</general><scope>6I.</scope><scope>AAFTH</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-4370-2008</orcidid></search><sort><creationdate>20190801</creationdate><title>Recommendations for the implementation of BRCA testing in ovarian cancer patients and their relatives</title><author>Gori, Stefania ; Barberis, Massimo ; Bella, Maria Angela ; Buttitta, Fiamma ; Capoluongo, Ettore ; Carrera, Paola ; Colombo, Nicoletta ; Cortesi, Laura ; Genuardi, Maurizio ; Gion, Massimo ; Guarneri, Valentina ; Incorvaia, Lorena ; La Verde, Nicla ; Lorusso, Domenica ; Marchetti, Antonio ; Marchetti, Paolo ; Normanno, Nicola ; Pasini, Barbara ; Pensabene, Matilde ; Pignata, Sandro ; Radice, Paolo ; Ricevuto, Enrico ; Sapino, Anna ; Tagliaferri, Pierosandro ; Tassone, Pierfrancesco ; Trevisiol, Chiara ; Truini, Mauro ; Varesco, Liliana ; Russo, Antonio</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c424t-1f7357d04ac58a6cffdb4fca9f6b0c18cc28d21374bdd9d35d7daa73c4df2c353</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>BRCA1</topic><topic>BRCA2</topic><topic>Genetic testing</topic><topic>Germline mutations</topic><topic>Ovarian cancer</topic><topic>PARP inhibitors</topic><topic>Somatic mutations</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Gori, Stefania</creatorcontrib><creatorcontrib>Barberis, Massimo</creatorcontrib><creatorcontrib>Bella, Maria Angela</creatorcontrib><creatorcontrib>Buttitta, Fiamma</creatorcontrib><creatorcontrib>Capoluongo, Ettore</creatorcontrib><creatorcontrib>Carrera, Paola</creatorcontrib><creatorcontrib>Colombo, Nicoletta</creatorcontrib><creatorcontrib>Cortesi, Laura</creatorcontrib><creatorcontrib>Genuardi, Maurizio</creatorcontrib><creatorcontrib>Gion, Massimo</creatorcontrib><creatorcontrib>Guarneri, Valentina</creatorcontrib><creatorcontrib>Incorvaia, Lorena</creatorcontrib><creatorcontrib>La Verde, Nicla</creatorcontrib><creatorcontrib>Lorusso, Domenica</creatorcontrib><creatorcontrib>Marchetti, Antonio</creatorcontrib><creatorcontrib>Marchetti, Paolo</creatorcontrib><creatorcontrib>Normanno, Nicola</creatorcontrib><creatorcontrib>Pasini, Barbara</creatorcontrib><creatorcontrib>Pensabene, Matilde</creatorcontrib><creatorcontrib>Pignata, Sandro</creatorcontrib><creatorcontrib>Radice, Paolo</creatorcontrib><creatorcontrib>Ricevuto, Enrico</creatorcontrib><creatorcontrib>Sapino, Anna</creatorcontrib><creatorcontrib>Tagliaferri, Pierosandro</creatorcontrib><creatorcontrib>Tassone, Pierfrancesco</creatorcontrib><creatorcontrib>Trevisiol, Chiara</creatorcontrib><creatorcontrib>Truini, Mauro</creatorcontrib><creatorcontrib>Varesco, Liliana</creatorcontrib><creatorcontrib>Russo, Antonio</creatorcontrib><creatorcontrib>On behalf of the AIOM-SIGU-SIBIOC-SIAPEC-IAP Working Group</creatorcontrib><creatorcontrib>AIOM-SIGU-SIBIOC-SIAPEC-IAP Working Group</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Critical reviews in oncology/hematology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Gori, Stefania</au><au>Barberis, Massimo</au><au>Bella, Maria Angela</au><au>Buttitta, Fiamma</au><au>Capoluongo, Ettore</au><au>Carrera, Paola</au><au>Colombo, Nicoletta</au><au>Cortesi, Laura</au><au>Genuardi, Maurizio</au><au>Gion, Massimo</au><au>Guarneri, Valentina</au><au>Incorvaia, Lorena</au><au>La Verde, Nicla</au><au>Lorusso, Domenica</au><au>Marchetti, Antonio</au><au>Marchetti, Paolo</au><au>Normanno, Nicola</au><au>Pasini, Barbara</au><au>Pensabene, Matilde</au><au>Pignata, Sandro</au><au>Radice, Paolo</au><au>Ricevuto, Enrico</au><au>Sapino, Anna</au><au>Tagliaferri, Pierosandro</au><au>Tassone, Pierfrancesco</au><au>Trevisiol, Chiara</au><au>Truini, Mauro</au><au>Varesco, Liliana</au><au>Russo, Antonio</au><aucorp>On behalf of the AIOM-SIGU-SIBIOC-SIAPEC-IAP Working Group</aucorp><aucorp>AIOM-SIGU-SIBIOC-SIAPEC-IAP Working Group</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Recommendations for the implementation of BRCA testing in ovarian cancer patients and their relatives</atitle><jtitle>Critical reviews in oncology/hematology</jtitle><addtitle>Crit Rev Oncol Hematol</addtitle><date>2019-08-01</date><risdate>2019</risdate><volume>140</volume><spage>67</spage><epage>72</epage><pages>67-72</pages><issn>1040-8428</issn><eissn>1879-0461</eissn><abstract>[Display omitted]
The current availability of new Poly(ADP-ribose) Polymerase (PARP)-inhibitors for the treatment of ovarian cancer patients independently of the presence of a BRCA pathogenic variant, together with the validation of somatic test for the analysis of BRCA1/2 genes, involves the need to optimise the guidelines for BRCA testing.
The AIOM-SIGU-SIBIOC-SIAPEC-IAP Italian Scientific Societies, in this position paper, recommend the implementation of BRCA testing with 2 main objectives: the first is the identification of ovarian cancer patients with higher probability of benefit from specific anticancer treatments (test for response to therapy); the second goal, through BRCA testing in the family members of ovarian cancer patients, is the identification of carriers of pathogenic variant, who have inheredited predisposition to cancer development (test for cancer risk). These individuals with increased risk of cancer, should be encouraged to participate in dedicated high-risk surveillance clinics and specific risk-reducing measures (primary and/or secondary prevention programs).</abstract><cop>Netherlands</cop><pub>Elsevier B.V</pub><pmid>31176273</pmid><doi>10.1016/j.critrevonc.2019.05.012</doi><tpages>6</tpages><orcidid>https://orcid.org/0000-0002-4370-2008</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1040-8428 |
| ispartof | Critical reviews in oncology/hematology, 2019-08, Vol.140, p.67-72 |
| issn | 1040-8428 1879-0461 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2242159178 |
| source | Access via ScienceDirect (Elsevier) |
| subjects | BRCA1 BRCA2 Genetic testing Germline mutations Ovarian cancer PARP inhibitors Somatic mutations |
| title | Recommendations for the implementation of BRCA testing in ovarian cancer patients and their relatives |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-22T08%3A24%3A17IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Recommendations%20for%20the%20implementation%20of%20BRCA%20testing%20in%20ovarian%20cancer%20patients%20and%20their%20relatives&rft.jtitle=Critical%20reviews%20in%20oncology/hematology&rft.au=Gori,%20Stefania&rft.aucorp=On%20behalf%20of%20the%20AIOM-SIGU-SIBIOC-SIAPEC-IAP%20Working%20Group&rft.date=2019-08-01&rft.volume=140&rft.spage=67&rft.epage=72&rft.pages=67-72&rft.issn=1040-8428&rft.eissn=1879-0461&rft_id=info:doi/10.1016/j.critrevonc.2019.05.012&rft_dat=%3Cproquest_cross%3E2242159178%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2242159178&rft_id=info:pmid/31176273&rft_els_id=S1040842819301040&rfr_iscdi=true |